Literature DB >> 8761016

Cannabinoid receptor stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding in rat brain membranes.

D E Selley1, S Stark, L J Sim, S R Childers.   

Abstract

Cannabinoid receptors belong to the class of G-protein-coupled receptors which inhibit adenylyl cyclase. Coupling of receptors to G-proteins can be assessed by the ability of agonists to stimulate guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTP gamma S) binding in the presence of excess GDP. The present study examined the effect of cannabinoid agonists on [35S]GTP gamma S binding in rat brain membranes. Assays were conducted with 0.05 nM [35S]GTP gamma S, incubated with rat cerebellar membranes, 1-30 microM GDP and the cannabinoid agonist WIN 55212-2. Results showed that the ability of WIN 55212-2 to stimulate [35S]GTP gamma S binding increased with increasing concentrations of GDP, with 10-30 microM GDP providing approximately 150-200% stimulation by the cannabinoid agonist. The pharmacology of cannabinoid agonist stimulation of [35S]GTP gamma S binding paralleled that of previously reported receptor binding and adenylyl cyclase assays, and agonist stimulation of [35S]GTP gamma S binding was blocked by the cannabinoid antagonist SR141716A. Brain regional studies revealed widespread stimulation of [35S]GTP gamma S binding by WIN 55212-2 in a number of brain areas, consistent with in vitro [35S]GTP gamma S autoradiography. These results demonstrate that [35S]GTP gamma S binding in the presence of excess GDP is an effective measure of cannabinoid receptor coupling to G-proteins in brain membranes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761016     DOI: 10.1016/0024-3205(96)00347-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  17 in total

Review 1.  Efficacy in CB1 receptor-mediated signal transduction.

Authors:  Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2004-08       Impact factor: 8.739

2.  Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.

Authors:  John W Huffman; Alicia L S Thompson; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2007-09-22       Impact factor: 3.641

3.  Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues.

Authors:  G Griffin; S Williams; M M Aung; R K Razdan; B R Martin; M E Abood
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.

Authors:  Travis W Grim; Kimberly L Samano; Bogna Ignatowska-Jankowska; Qing Tao; Laura J Sim-Selly; Dana E Selley; Laura E Wise; Alphonse Poklis; Aron H Lichtman
Journal:  J Basic Clin Physiol Pharmacol       Date:  2016-05-01

5.  Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.

Authors:  D Matthew Walentiny; Robert E Vann; Jonathan A Warner; Lindsey S King; Herbert H Seltzman; Hernán A Navarro; Charles E Twine; Brian F Thomas; Anne F Gilliam; Brian P Gilmour; F Ivy Carroll; Jenny L Wiley
Journal:  Psychopharmacology (Berl)       Date:  2010-03-31       Impact factor: 4.530

6.  Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays.

Authors:  T W Grim; A J Morales; M M Gonek; J L Wiley; B F Thomas; G W Endres; L J Sim-Selley; D E Selley; S S Negus; A H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2016-08-17       Impact factor: 4.030

7.  3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.

Authors:  Jenny L Wiley; Dana E Selley; Pinglang Wang; Rudresha Kottani; Srinivas Gadthula; Anu Mahadeven
Journal:  J Pharmacol Exp Ther       Date:  2011-11-15       Impact factor: 4.030

8.  Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.

Authors:  Jenny L Wiley; Christopher S Breivogel; Anu Mahadevan; Roger G Pertwee; Maria Grazia Cascio; Daniele Bolognini; John W Huffman; D Matthew Walentiny; Robert E Vann; Raj K Razdan; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2010-11-27       Impact factor: 4.432

Review 9.  Activation of G-proteins in brain by endogenous and exogenous cannabinoids.

Authors:  Steven R Childers
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

10.  Molecules Acting on CB1 Receptor and their Effects on Morphine Withdrawal In Vitro.

Authors:  Anna Capasso; Chiara Gallo
Journal:  Open Biochem J       Date:  2009-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.